Ending weight loss drug therapy linked to weight regain
Researchers report that ending the use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is associated with weight regain and a reversal of heart health markers. The […]
Researchers report that ending the use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is associated with weight regain and a reversal of heart health markers. The […]
When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom scale. According to new Cornell University research, the medications are associated […]
Nearly half of U.S. adults say starting a new diet is one of their New Year’s resolutions, according to a new Physicians Committee for Responsible Medicine/Morning Consult survey. More […]
As teens gain more independence in their food choices, many parents struggle to navigate conversations about nutrition —which could be especially important during the holidays, when celebrations often […]
New research reveals that more than 7 in 10 (71%) women have consumed alcohol-free or low-alcohol drinks during pregnancy, signalling their growing popularity among expectant mothers seeking safer […]
The EU drug watchdog, the European Medicines Agency (EMA), has launched a partnership with social media influencers to promote the safe use of GLP-1 receptor agonists. The #HealthNotHype […]
In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain […]
Food companies are driving a global rise in ultra-processed food consumption that is damaging our health, and also preventing government action that could limit its harm, an international study reveals. […]
Orforglipron , an investigative and oral GLP-1 drug, appears to enable adults with obesity and Type 2 diabetes to achieve significantly more weight loss and improvement in blood […]
New research is uncovering how medications targeting the glucagon-like peptide-1 (GLP-1) system affect brain circuits involved in nausea, thirst, and pleasurable behaviors. These findings will be presented at […]
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that […]
A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight […]
ADVERTISMENT
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.